Institution
University of Erlangen-Nuremberg
Education•Erlangen, Bayern, Germany•
About: University of Erlangen-Nuremberg is a education organization based out in Erlangen, Bayern, Germany. It is known for research contribution in the topics: Population & Immune system. The organization has 42405 authors who have published 85600 publications receiving 2663922 citations.
Topics: Population, Immune system, Catalysis, Medicine, Computer science
Papers published on a yearly basis
Papers
More filters
••
University of Paris1, Medical University of Vienna2, Leiden University3, Paris Descartes University4, University of Leeds5, Ruhr University Bochum6, Charité7, University College Dublin8, Halmstad University9, Katholieke Universiteit Leuven10, University of Münster11, University of Glasgow12, Charles University in Prague13, University of Erlangen-Nuremberg14, Ghent University Hospital15
TL;DR: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
Abstract: Background Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
802 citations
••
Massachusetts Institute of Technology1, University of Erlangen-Nuremberg2, Max Delbrück Center for Molecular Medicine3, Charité4, ETH Zurich5, University of Regensburg6, Dresden University of Technology7, University of Hasselt8, Robert Koch Institute9, Hannover Medical School10, National Institutes of Health11, Vanderbilt University12
TL;DR: This paper showed that high salt intake affects the gut microbiome in mice, particularly by depleting Lactobacillus murinus, and treatment of mice with L. murinus prevented salt-induced aggravation of actively induced experimental autoimmune encephalomyelitis and salt-sensitive hypertension by modulating T helper 17 (TH17) cells.
Abstract: A Western lifestyle with high salt consumption can lead to hypertension and cardiovascular disease. High salt may additionally drive autoimmunity by inducing T helper 17 (TH17) cells, which can also contribute to hypertension. Induction of TH17 cells depends on gut microbiota; however, the effect of salt on the gut microbiome is unknown. Here we show that high salt intake affects the gut microbiome in mice, particularly by depleting Lactobacillus murinus. Consequently, treatment of mice with L. murinus prevented salt-induced aggravation of actively induced experimental autoimmune encephalomyelitis and salt-sensitive hypertension by modulating TH17 cells. In line with these findings, a moderate high-salt challenge in a pilot study in humans reduced intestinal survival of Lactobacillus spp., increased TH17 cells and increased blood pressure. Our results connect high salt intake to the gut-immune axis and highlight the gut microbiome as a potential therapeutic target to counteract salt-sensitive conditions.
802 citations
••
TL;DR: This work determines the precise glycan requirements for this anti-inflammatory activity of IgG, allowing us to engineer an appropriate IgG1 Fc fragment, and thus generate a fully recombinant, sialylated IgG 1 Fc with greatly enhanced potency.
Abstract: It is well established that high doses of monomeric immunoglobulin G (IgG) purified from pooled human plasma [intravenous immunoglobulin (IVIG)] confer anti-inflammatory activity in a variety of autoimmune settings. However, exactly how those effects are mediated is not clear because of the heterogeneity of IVIG. Recent studies have demonstrated that the anti-inflammatory activity of IgG is completely dependent on sialylation of the N-linked glycan of the IgG Fc fragment. Here we determine the precise glycan requirements for this anti-inflammatory activity, allowing us to engineer an appropriate IgG1 Fc fragment, and thus generate a fully recombinant, sialylated IgG1 Fc with greatly enhanced potency. This therapeutic molecule precisely defines the biologically active component of IVIG and helps guide development of an IVIG replacement with improved activity and availability.
798 citations
••
Carlos III Health Institute1, University of Brescia2, University of Glasgow3, Istanbul University4, Haukeland University Hospital5, University of Erlangen-Nuremberg6, University of Valencia7, Heidelberg University8, Charles University in Prague9, Guy's and St Thomas' NHS Foundation Trust10, Aristotle University of Thessaloniki11, University of Manchester12, University of Milan13
TL;DR: The recommendations of the present document represent the best clinical wisdom upon which physicians, nurses and families should base their decisions and should encourage public policy makers to develop a global effort to improve identification and treatment of high blood pressure among children and adolescents.
Abstract: Increasing prevalence of hypertension (HTN) in children and adolescents has become a significant public health issue driving a considerable amount of research. Aspects discussed in this document include advances in the definition of HTN in 16 year or older, clinical significance of isolated systolic HTN in youth, the importance of out of office and central blood pressure measurement, new risk factors for HTN, methods to assess vascular phenotypes, clustering of cardiovascular risk factors and treatment strategies among others. The recommendations of the present document synthesize a considerable amount of scientific data and clinical experience and represent the best clinical wisdom upon which physicians, nurses and families should base their decisions. In addition, as they call attention to the burden of HTN in children and adolescents, and its contribution to the current epidemic of cardiovascular disease, these guidelines should encourage public policy makers to develop a global effort to improve identification and treatment of high blood pressure among children and adolescents.
795 citations
••
TL;DR: It is important to study the crosstalk between MSCs and innate immunity, which ranges from the bone marrow niche to injured tissue, and to identify components of the innate immune system also have a key role.
Abstract: Multipotent mesenchymal stromal cells (MSCs) have unique immunoregulatory and regenerative properties that make them an attractive tool for the cellular treatment of autoimmunity and inflammation. Their underlying molecular mechanisms of action together with their clinical benefit - for example, in autoimmunity - are being revealed by an increasing number of clinical trials and preclinical studies of MSCs. However, autoimmunity and therapy-related alloimmunity are not only triggered and sustained by responses of the adaptive immune system; there is growing evidence that components of the innate immune system also have a key role. It is therefore important to study the crosstalk between MSCs and innate immunity, which ranges from the bone marrow niche to injured tissue.
790 citations
Authors
Showing all 42831 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hermann Brenner | 151 | 1765 | 145655 |
Richard B. Devereux | 144 | 962 | 116403 |
Manfred Paulini | 141 | 1791 | 110930 |
Daniel S. Berman | 141 | 1363 | 86136 |
Peter Lang | 140 | 1136 | 98592 |
Joseph Sodroski | 138 | 542 | 77070 |
Richard J. Johnson | 137 | 880 | 72201 |
Jun Lu | 135 | 1526 | 99767 |
Michael Schmitt | 134 | 2007 | 114667 |
Jost B. Jonas | 132 | 1158 | 166510 |
Andreas Mussgiller | 127 | 1059 | 73778 |
Matthew J. Budoff | 125 | 1449 | 68115 |
Stefan Funk | 125 | 506 | 56955 |
Markus F. Neurath | 124 | 934 | 62376 |
Jean-Marie Lehn | 123 | 1054 | 84616 |